Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)

[1]  H. Stellbrink,et al.  Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Muriel,et al.  Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study , 2021, Journal of the International AIDS Society.

[3]  H. Günthard,et al.  Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV , 2021, Annals of Internal Medicine.

[4]  G. Maartens,et al.  Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. , 2020, The lancet. HIV.

[5]  H. Jessen,et al.  Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial , 2020, The Lancet.

[6]  T. Cotter,et al.  Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .

[7]  J. Milic,et al.  Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus , 2020, Clinical Infectious Diseases.

[8]  Richard D Moore,et al.  Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada , 2020, Journal of the International AIDS Society.

[9]  K. White,et al.  Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight , 2020, PloS one.

[10]  F. Villarroya,et al.  Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV , 2020, International Journal of Obesity.

[11]  V. Wong,et al.  FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study , 2020, The lancet. Gastroenterology & hepatology.

[12]  J. Rockstroh,et al.  Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials , 2019, Journal of acquired immune deficiency syndromes.

[13]  C. Yanavich,et al.  Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono‐infection under long‐term combined antiretroviral therapy , 2018, Journal of the International AIDS Society.

[14]  J. Bogner,et al.  A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017 , 2018, Infection.

[15]  R. D. De Boni,et al.  Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors , 2018, The Journal of antimicrobial chemotherapy.

[16]  D. Glidden,et al.  Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Rockstroh,et al.  Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis , 2018, Medicine.

[18]  S. Bhagani,et al.  Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies. , 2018, Journal of acquired immune deficiency syndromes.

[19]  G. Baffy.  Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? , 2018, Advances in experimental medicine and biology.

[20]  Sally S Bebawy,et al.  Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens , 2017, Journal of acquired immune deficiency syndromes.

[21]  P. Tien,et al.  Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults , 2017, AIDS.

[22]  M. Thursz,et al.  Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection , 2017, AIDS.

[23]  P. Brouqui,et al.  Dolutegravir and weight gain: an unexpected bothering side effect? , 2017, AIDS.

[24]  J. Rockstroh.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV , 2017, Current HIV/AIDS Reports.

[25]  J. Routy,et al.  Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients , 2016, AIDS.

[26]  M. Charlton,et al.  The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health , 2016, Hepatology.

[27]  J. Rockstroh,et al.  Liver Fibrosis in HIV Patients Receiving a Modern cART , 2015, Medicine.

[28]  R. Weber,et al.  Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy , 2015, PloS one.

[29]  D. Leaf,et al.  Weight change after antiretroviral therapy and mortality. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  G. Sebastiani,et al.  Incidence and Predictors of Hepatic Steatosis and Fibrosis by Serum Biomarkers in a Large Cohort of Human Immunodeficiency Virus Mono-Infected Patients , 2015, Open forum infectious diseases.

[31]  J. Rockstroh,et al.  Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? , 2014, Current opinion in HIV and AIDS.

[32]  C. Tural,et al.  Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients , 2014, AIDS.

[33]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. , 2014, Journal of hepatology.

[34]  M. Budoff,et al.  Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study , 2014, The American Journal of Gastroenterology.

[35]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[36]  S. Chow,et al.  Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. , 2013, AIDS research and human retroviruses.

[37]  R. Sterling,et al.  Hepatic Steatosis in Human Immunodeficiency Virus: A Prospective Study in Patients Without Viral Hepatitis, Diabetes, or Alcohol Abuse , 2013, Journal of clinical gastroenterology.

[38]  Laurent Castera,et al.  Noninvasive methods to assess liver disease in patients with hepatitis B or C. , 2012, Gastroenterology.

[39]  Giorgio Saracco,et al.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.

[40]  G. Ligabue,et al.  Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.